{
    "xml": "<topic id=\"PHP6635\" outputclass=\"drug\" rev=\"1.18\" type=\"drug\" namespace=\"/drugs/belimumab\" basename=\"belimumab\" title=\"BELIMUMAB\">\n<title>BELIMUMAB</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1221\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/monoclonal-antibodies/belimumab\">Belimumab</xref>\n</p>\n<data name=\"vtmid\">704193005</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_402717286\" title=\"Monoclonal antibodies (anti-lymphocyte)\">Monoclonal antibodies (anti-lymphocyte)</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP48351\" outputclass=\"indicationsAndDose\" rev=\"1.19\" parent=\"/drugs/belimumab\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Adjunctive therapy in patients with active, autoantibody-positive systemic lupus erythematosus with a high degree of disease activity despite standard therapy</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>10&#8239;mg/kg every 2&#8239;weeks for 3 doses, then 10&#8239;mg/kg every 4&#8239;weeks, review treatment if no response within 6 months.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48494\" outputclass=\"cautions\" rev=\"1.8\" parent=\"/drugs/belimumab\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Do not initiate until active infections controlled</ph>; <ph outputclass=\"caution\">history or development of malignancy</ph>; <ph outputclass=\"caution\">predisposition to infection</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48334\" outputclass=\"interactions\" rev=\"1.8\" parent=\"/drugs/belimumab\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (belimumab).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48214\" outputclass=\"sideEffects\" rev=\"1.14\" parent=\"/drugs/belimumab\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Infusion-related reactions</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Depression</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">hypersensitivity reactions</ph>; <ph outputclass=\"sideEffect\">infections</ph>; <ph outputclass=\"sideEffect\">insomnia</ph>; <ph outputclass=\"sideEffect\">leucopenia</ph>; <ph outputclass=\"sideEffect\">migraine</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">pain in extremities</ph>; <ph outputclass=\"sideEffect\">pyrexia</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p>Infusion-related side-effects are reported commonly, including severe or life-threatening hypersensitivity and infusion reactions. Premedication with an antihistamine, with or without an antipyretic may be considered.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48482\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/belimumab\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises adequate contraception during treatment and for at least 4 months after last dose.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48309\" outputclass=\"pregnancy\" parent=\"/drugs/belimumab\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid unless essential.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48511\" outputclass=\"breastFeeding\" parent=\"/drugs/belimumab\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid&#8212;present in milk in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48243\" outputclass=\"renalImpairment\" parent=\"/drugs/belimumab\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Caution in severe impairment&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48159\" outputclass=\"monitoringRequirements\" parent=\"/drugs/belimumab\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Delay in the onset of acute hypersensitivity reactions has been observed; patients should remain under clinical supervision for several hours following at least the first 2 infusions.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP48539\" outputclass=\"directionsForAdministration\" rev=\"1.15\" parent=\"/drugs/belimumab\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>For <i>intravenous infusion</i> (<i>Benlysta</i>\n<tm tmtype=\"reg\"/>), give intermittently in Sodium chloride 0.9%; reconstitute with water for injections (120&#8239;mg in 1.5&#8239;mL, 400&#8239;mg in 4.8&#8239;mL) to produce a solution containing 80&#8239;mg/mL; gently swirl vial for 60 seconds, then allow to stand; swirl vial (without shaking) for 60 seconds every 5 minutes until dissolved; dilute requisite dose with infusion fluid to a final volume of 250&#8239;mL and give over 1 hour.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP6635-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/belimumab\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76752\" title=\"Powder for solution for infusion\" namespace=\"/drugs/belimumab/powder-for-solution-for-infusion\">Powder for solution for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78421\" namespace=\"/treatment-summaries/rheumatic-disease-suppressing-drugs\" title=\"Rheumatic disease, suppressing drugs\" count=\"2\" rel=\"backlink\">Rheumatic disease, suppressing drugs</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1221\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/monoclonal-antibodies/belimumab\" title=\"Belimumab\" count=\"1\" rel=\"link\">Belimumab</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76752\" namespace=\"/drugs/belimumab/powder-for-solution-for-infusion\" title=\"Powder for solution for infusion\" count=\"1\" rel=\"link\">Powder for solution for infusion</xref>\n</links>\n</topic>",
    "id": "PHP6635",
    "outputclass": "drug",
    "rev": "1.18",
    "type": "drug",
    "namespace": "/drugs/belimumab",
    "basename": "belimumab",
    "title": "BELIMUMAB",
    "interactants": [
        {
            "id": "bnf_int_1221",
            "label": "Belimumab"
        }
    ],
    "vtmid": "704193005",
    "drugClassification": [
        "Monoclonal antibodies (anti-lymphocyte)"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Adjunctive therapy in patients with active, autoantibody-positive systemic lupus erythematosus with a high degree of disease activity despite standard therapy",
                        "html": "Adjunctive therapy in patients with active, autoantibody-positive systemic lupus erythematosus with a high degree of disease activity despite standard therapy"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "10 mg/kg every 2 weeks for 3 doses, then 10 mg/kg every 4 weeks, review treatment if no response within 6 months.",
                        "html": "<p>10&#8239;mg/kg every 2&#8239;weeks for 3 doses, then 10&#8239;mg/kg every 4&#8239;weeks, review treatment if no response within 6 months.</p>"
                    }
                ]
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Do not initiate until active infections controlled",
                "html": "Do not initiate until active infections controlled"
            },
            {
                "type": "cautions",
                "textContent": "history or development of malignancy",
                "html": "history or development of malignancy"
            },
            {
                "type": "cautions",
                "textContent": "predisposition to infection",
                "html": "predisposition to infection"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (belimumab).",
                "html": "<p>Appendix 1 (belimumab).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Infusion-related reactions",
                        "html": "Infusion-related reactions",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Depression",
                        "html": "Depression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypersensitivity reactions",
                        "html": "hypersensitivity reactions",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "infections",
                        "html": "infections",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "insomnia",
                        "html": "insomnia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "leucopenia",
                        "html": "leucopenia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "migraine",
                        "html": "migraine",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pain in extremities",
                        "html": "pain in extremities",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pyrexia",
                        "html": "pyrexia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "textContent": "Infusion-related side-effects are reported commonly, including severe or life-threatening hypersensitivity and infusion reactions. Premedication with an antihistamine, with or without an antipyretic may be considered.",
                "html": "<p>Infusion-related side-effects are reported commonly, including severe or life-threatening hypersensitivity and infusion reactions. Premedication with an antihistamine, with or without an antipyretic may be considered.</p>"
            }
        ]
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises adequate contraception during treatment and for at least 4 months after last dose.",
                "html": "<p>Manufacturer advises adequate contraception during treatment and for at least 4 months after last dose.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid unless essential.",
                "html": "<p>Avoid unless essential.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid&#8212;present in milk in animal studies.",
                "html": "<p>Avoid&#8212;present in milk in <i>animal</i> studies.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Caution in severe impairment&#8212;no information available.",
                "html": "<p>Caution in severe impairment&#8212;no information available.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Delay in the onset of acute hypersensitivity reactions has been observed; patients should remain under clinical supervision for several hours following at least the first 2 infusions.",
                "html": "<p>Delay in the onset of acute hypersensitivity reactions has been observed; patients should remain under clinical supervision for several hours following at least the first 2 infusions.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "For intravenous infusion (Benlysta ), give intermittently in Sodium chloride 0.9%; reconstitute with water for injections (120 mg in 1.5 mL, 400 mg in 4.8 mL) to produce a solution containing 80 mg/mL; gently swirl vial for 60 seconds, then allow to stand; swirl vial (without shaking) for 60 seconds every 5 minutes until dissolved; dilute requisite dose with infusion fluid to a final volume of 250 mL and give over 1 hour.",
                "html": "<p>For <i>intravenous infusion</i> (<i>Benlysta</i>\n<tm tmtype=\"reg\"/>), give intermittently in Sodium chloride 0.9%; reconstitute with water for injections (120&#8239;mg in 1.5&#8239;mL, 400&#8239;mg in 4.8&#8239;mL) to produce a solution containing 80&#8239;mg/mL; gently swirl vial for 60 seconds, then allow to stand; swirl vial (without shaking) for 60 seconds every 5 minutes until dissolved; dilute requisite dose with infusion fluid to a final volume of 250&#8239;mL and give over 1 hour.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76752",
                "label": "Powder for solution for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78421",
                "label": "Rheumatic disease, suppressing drugs",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1221",
                "label": "Belimumab",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76752",
                "label": "Powder for solution for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}